Verona Pharma VRNA Stock
Verona Pharma Price Chart
Verona Pharma VRNA Financial and Trading Overview
| Verona Pharma stock price | 65.46 USD |
| Previous Close | 21.51 USD |
| Open | 21.54 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 800 |
| Day's Range | 20.72 - 21.54 USD |
| 52 Week Range | 3.85 - 26.44 USD |
| Volume | 486.58K USD |
| Avg. Volume | 500.47K USD |
| Market Cap | 1.68B USD |
| Beta (5Y Monthly) | 0.191549 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.16 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.43 USD |
VRNA Valuation Measures
| Enterprise Value | 1.44B USD |
| Trailing P/E | N/A |
| Forward P/E | -19.2 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 3664.1082 |
| Price/Book (mrq) | 6.029118 |
| Enterprise Value/Revenue | 3140.305 |
| Enterprise Value/EBITDA | -23.345 |
Trading Information
Verona Pharma Stock Price History
| Beta (5Y Monthly) | 0.191549 |
| 52-Week Change | 404.05% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 26.44 USD |
| 52 Week Low | 3.85 USD |
| 50-Day Moving Average | 21.39 USD |
| 200-Day Moving Average | 17.6 USD |
VRNA Share Statistics
| Avg. Volume (3 month) | 500.47K USD |
| Avg. Daily Volume (10-Days) | 314.52K USD |
| Shares Outstanding | 79.46M |
| Float | 56.02M |
| Short Ratio | 5.59 |
| % Held by Insiders | 3.14% |
| % Held by Institutions | 69.93% |
| Shares Short | 2.65M |
| Short % of Float | N/A |
| Short % of Shares Outstanding | 3.32% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -13589.29% |
| Gross Margin | 24.45% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -15.79% |
| Return on Equity (ttm) | -30.074% |
Income Statement
| Revenue (ttm) | 458K USD |
| Revenue Per Share (ttm) | 0.006 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 112K USD |
| EBITDA | -61609000 USD |
| Net Income Avi to Common (ttm) | -60607000 USD |
| Diluted EPS (ttm) | -0.87 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 291.42M USD |
| Total Cash Per Share (mrq) | 3.67 USD |
| Total Debt (mrq) | 20.52M USD |
| Total Debt/Equity (mrq) | 7.42 USD |
| Current Ratio (mrq) | 11.571 |
| Book Value Per Share (mrq) | 3.503 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -51132000 USD |
| Levered Free Cash Flow (ttm) | -30743624 USD |
Profile of Verona Pharma
| Country | United States |
| State | N/A |
| City | London |
| Address | 3 More London Riverside |
| ZIP | SE1 2RE |
| Phone | 44 20 3283 4200 |
| Website | https://www.veronapharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 35 |
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Q&A For Verona Pharma Stock
What is a current VRNA stock price?
Verona Pharma VRNA stock price today per share is 65.46 USD.
How to purchase Verona Pharma stock?
You can buy VRNA shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Verona Pharma?
The stock symbol or ticker of Verona Pharma is VRNA.
Which industry does the Verona Pharma company belong to?
The Verona Pharma industry is Biotechnology.
How many shares does Verona Pharma have in circulation?
The max supply of Verona Pharma shares is 131.72M.
What is Verona Pharma Price to Earnings Ratio (PE Ratio)?
Verona Pharma PE Ratio is now.
What was Verona Pharma earnings per share over the trailing 12 months (TTM)?
Verona Pharma EPS is -2.16 USD over the trailing 12 months.
Which sector does the Verona Pharma company belong to?
The Verona Pharma sector is Healthcare.
Verona Pharma VRNA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| NASDAQ Global Market Composite NQGM | 1839.71 USD — |
-3.16
|
— — | 1825.54 USD — | 1881.06 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4131.38 USD — |
-1.41
|
— — | 4109.33 USD — | 4165.2 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4148.65 USD — |
+0.54
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
- {{ link.label }} {{link}}